Examkin

Soru

Zorluk: ZorHealthcare Economics and Value-Based Care

A 32-year-old man presents to the emergency department with a 1-day history of right-sided chest pain that worsens with deep inspiration. He has no significant past medical history. Three weeks ago, he underwent uncomplicated arthroscopic right knee surgery for a meniscus tear. Vital signs include a temperature of 37.1°C (98.8°F), blood pressure of 122/78 mm Hg, pulse of 94/min, respiratory rate of 16/min, and oxygen saturation of 98% on room air. Physical examination reveals clear lungs bilaterally, a normal cardiovascular exam, and no unilateral leg swelling or calf tenderness. A first-year resident suggests immediately ordering a computed tomography pulmonary angiography (CTPA) to rapidly rule out pulmonary embolism (PE), citing the recent surgery as a major risk factor. The attending physician notes that the patient's modified Wells score is 1.5 (low probability category) but he fails the Pulmonary Embolism Rule-out Criteria (PERC) due to the recent surgery. The emergency department has recently implemented a value-based care initiative to minimize unnecessary advanced imaging, lower healthcare costs, and reduce iatrogenic radiation exposure. Which of the following is the most cost-effective and appropriate next step in management?

  1. Order a high-sensitivity plasma D-dimer assayCevap
  2. B
    Order computed tomography pulmonary angiography (CTPA)
  3. C
    Order a ventilation-perfusion (V/Q) scan
  4. D
    Perform a bilateral lower extremity venous duplex ultrasound
  5. E
    Discharge the patient with reassurance and oral NSAIDs

Cevap

The most appropriate next step is to order a high-sensitivity plasma D-dimer assay.
Diagnostic stewardship is a core component of healthcare economics. For a patient with a low pre-test probability of pulmonary embolism (Wells score < 2 or <= 4 depending on the tier system used) who cannot be clinically cleared by the PERC rule, the standard of care is to order a high-sensitivity D-dimer. If the D-dimer is negative, PE is effectively ruled out, and no further imaging is required. This pathway maximizes healthcare value by reserving expensive, resource-intensive, and potentially harmful advanced imaging (like CTPA) only for patients with an elevated D-dimer or those with a high baseline clinical probability.

Adım Adım Çözüm

1
Assess the patient's pre-test probability for pulmonary embolism (PE).
The patient has a modified Wells score of 1.5 (1.5 points for recent surgery, no other signs), placing him in the low-probability group.
Stratifying risk is the first principle of high-value diagnostic stewardship to determine the appropriate testing pathway.
2
Determine if the patient can be entirely excluded from testing using clinical criteria.
The patient fails the Pulmonary Embolism Rule-out Criteria (PERC) solely because of the recent surgery (within 4 weeks).
PERC is used in low-risk patients to avoid any testing, but failing it means some objective testing is necessary.
3
Select the most cost-effective and least harmful initial diagnostic test.
A high-sensitivity plasma D-dimer is selected over immediate CTPA.
In low-probability patients, D-dimer has a high negative predictive value. A negative result safely rules out PE, preventing the high financial cost, radiation exposure, and potential contrast nephropathy associated with CTPA.

Anahtar Kavram

In patients with a low pre-test probability of pulmonary embolism who do not meet PERC rule-out criteria, obtaining a high-sensitivity D-dimer is the most cost-effective, high-value diagnostic step before considering advanced imaging.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Healthcare Economics and Value-Based Care

Bu konudan daha fazla soru